Migraine Connect
  • Saved

4yr
Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies - PubMed

Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35687795/

doi: 10.1002/brb3.2662. Online ahead of print. 1 Department of Neurology and Centre for Translational Neuro- and Behavioural Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany....


Conclusion: A mandatory break in CGRP (pathway) monoclonal antibody therapy had a negative short-term impact on migraine patients.

  • 4yr
    I wonder if this is necessary to do.
  • 4yr
    Key Points • Source: Brain and Behavior • Conclusions: “A mandatory break in CGRP (pathway) monoclonal antibody therapy had a negative short-term impact on migraine patients.” • The investigators assessed clinical data from 46 migraine patients: Show More
  • Saved

4yr
Machine-learning based approach to predict anti-CGRP response in patients with migraine: multicenter Spanish study - PubMed

Machine-learning based approach to predict anti-CGRP response in patients with migraine: multicenter Spanish study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35726393/

doi: 10.1111/ene.15458. Online ahead of print. 1 Headache Unit, Neurology Department, Hospital Universitario de la Princesa & Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. 2 Universidad Politécnica de Madrid...


Conclusions: According to our study, ML models can predict anti-CGRP response at 6, 9 and 12 months. This study provides a predictive tool to be used in a real-world setting.cts as previously reported.

  • Saved

4yr
Safety profile of lasmiditan in patients with migraine in an Asian population

Safety profile of lasmiditan in patients with migraine in an Asian population

Source : https://www.tandfonline.com/doi/abs/10.1080/14740338.2022.2087630?journalCode=ieds20

ABSTRACT MONONOFU, a multicenter, randomized, double-blind, placebo-controlled phase 2 study of Japanese patients with migraine, was pivotal for lasmiditan approval in Japan. However, treatment-emergent adverse events (TEAEs) were more common...


Conclusions: In the MONONOFU study, TEAEs appeared typically mild, transient, and self-limiting. Lasmiditan may represent a useful and well-tolerated acute treatment option for smaller (body mass index

  • Saved

4yr
Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects - Clinical Drug Investigation

Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects - Clinical Drug Investigation

Source : https://link.springer.com/article/10.1007/s40261-022-01171-5

Background and Objective Erenumab is the first-in-class, selective, and competitive human monoclonal antibody antagonist of the calcitonin gene-related peptide (CGRP) receptor that has been shown to be effective and well-tolerated...


Conclusions: Erenumab was safe and well tolerated after a single subcutaneous injection in healthy Chinese subjects. The systemic exposure in Chinese subjects in terms of AUC0-∞ was 70% higher than that in White subjects as previously reported.

  • Saved

4yr
Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE - BMC Neurology

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE - BMC Neurology

Source : https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-022-02710-5

Background Erenumab is a fully human monoclonal antibody and a highly potent, first-in-class calcitonin gene-related peptide receptor inhibitor approved for migraine prevention in adults. Randomised, placebo-controlled trials show that erenumab...


Conclusion: In this real-world study on erenumab use in the UAE, patients prescribed erenumab achieved clinically meaningful reductions in MHD and MSMD at all assessed time points. Erenumab was well tolerated with no new safety events.